2024-519808-27-00暂停1/2 期
Application of antiCD19 CAR T lymphocytes for the treatment of adult patients with B-cell acute lymphoblastic leukemia with resistance, relapse or detectable measurable residual disease. Phase I/II clinical trial (MERMAID1)
Medical University Of Warsaw3 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2025年1月30日最近更新:
试验速览
- 阶段
- 1/2 期
- 状态
- 暂停
- 发起方
- 入组人数
- 20
- 试验地点
- 3
- 主要终点
- Percentage of patients with treatment-emergent adverse event (TEAE) Grade ≥ 3 within 12 weeks after treatment of therapies of particular interest, i.e.: o Cytokine Release Syndrome (CRS)o Neurological Adverse Events (ICANS) o Infections o Febrile neutropenia o Persistent cytopenias (i.e. more than 28 days after CAR T cell administration) o Tumor lysis syndrome (TLS)
研究概览
简要总结
The aim of the study is to evaluate the safety and efficacy of anti-CD19 CAR T cells in the treatment of acute lymphoblastic leukemia Bcell with resistance, relapse or with positive measurable residual disease (MRD+) in adults.
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Diagnosis of B-ALL on blast cells at the time of resistance, relapse, or measurable residual disease (MRD)
- •In men capable of having children, declaration of refraining from heterosexual sexual intercourse or using an appropriate method of contraception (as in point 4.3) by themselves and/or their partners (if capable of having children) after signing an informed consent for a period of 12 months from the start of therapy CAR-T.
- •Resistance, relapse, or presence of MRD defined as at least 0.01% of leukemic lymphoblasts among bone marrow cells.
- •Prior use of at least two cycles of chemotherapy
- •Age >18 years on screening date
- •Performance status assessed in the ECOG (Eastern Cooperative Oncology Group) scale of ≤ 2
- •Satisfactory organ function during screening: A. ALT / AST activity <4 x Upper Limit of Normal (ULN) and total bilirubin <2 mg / dL (<4 mg / dL in patients with Gilbert's syndrome); B. Ejection fraction (EF)> 40% confirmed by ECHO, with no significant pericardial effusion within 6 weeks prior to screening; C. Respiratory capacity: arterial blood saturation> 92% without oxygen therapy, no significant pleural effusion; D. Creatinine clearance> 30 ml / min
- •Understanding and providing informed consent to participate in the study;
- •Negative pregnancy test (serum) in women of childbearing age.
- •In women capable of having children, a declaration to refrain from heterosexual sexual intercourse or to use an appropriate method of contraception (as in point 4.3) after signing the informed consent form for a period of 12 months after the use of CAR-T therapy. If hormonal contraception is used, the period of use must begin at least one month before the use of CAR-T therapy. If hormonal contraception is used, the period of its use must start at least one month before the use of CAR-T therapy.
排除标准
- •Diagnosis of B-cell lymphoblastic lymphoma (presence of <20% leukemic blasts in blood or bone marrow at diagnosis)
- •Platelet count <50,000/μL unless, in the opinion of the investigator, the cytopenia is potentially reversible
- •Absolute lymphocyte count <100/μL
- •Other co-morbidities that have been assessed as likely to interfere with the conduct of the study, as assessed by the investigator
- •Pregnancy or breastfeeding
- •Women of childbearing potential or men who do not consent to the use of an effective method of contraception (as in section 4.3) while participating in the study
- •Inability to give informed consent to participate in a study
- •Isolated central nervous system (CNS) relapse
- •History of significant diseases of the central nervous system (CNS) or significant current CNS disorders (seizures, paralysis, aphasia, CNS ischemia / hemorrhage, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, psychosis and diseases associated with incoordination or movement disorders)
- •The need for systemic immunosuppressive therapy
- •Allogeneic hematopoietic cells (alloHCT) transplant surgery in less than 3 months prior to screening
- •Concurrent presence of another neoplasm and another neoplasm diagnosed up to 2 years prior to study enrollment
- •Active bacterial, viral or fungal infections, including SARS-CoV2
- •Positive serology results towards HIV (antigene and/or anti-HIV), HBV ( HbsAg and/ or anti-HbsAg) and HCV ( anti-HCV)
- •Absolute neutrophil count <500/μL unless, in the opinion of the investigator, the cytopenia is potentially reversible
结局指标
主要结局
Percentage of patients with treatment-emergent adverse event (TEAE) Grade ≥ 3 within 12 weeks after treatment of therapies of particular interest, i.e.: o Cytokine Release Syndrome (CRS)o Neurological Adverse Events (ICANS) o Infections o Febrile neutropenia o Persistent cytopenias (i.e. more than 28 days after CAR T cell administration) o Tumor lysis syndrome (TLS)
Percentage of patients with treatment-emergent adverse event (TEAE) Grade ≥ 3 within 12 weeks after treatment of therapies of particular interest, i.e.: o Cytokine Release Syndrome (CRS)o Neurological Adverse Events (ICANS) o Infections o Febrile neutropenia o Persistent cytopenias (i.e. more than 28 days after CAR T cell administration) o Tumor lysis syndrome (TLS)
Overall response rate (ORR) to treatment, defined as complete remission (CR) and complete remission with incomplete haematopoietic recovery (CRi)
Overall response rate (ORR) to treatment, defined as complete remission (CR) and complete remission with incomplete haematopoietic recovery (CRi)
次要结局
- Percentage of patients with SAE during the observation period, taking into account their severity and the causal relationship with the applied treatment
- Disease-free percentage at 1, 3, 6, 12, 18 and 24 months post-infusion ie complete remission (CR) or complete remission with incomplete haematopoietic recovery (CRi) with negative minimal residual disease (MRD-) cytometrically assessed
- Progression-Free Survival (PFS); Time from CAR-T infusion to relapse or death from any cause
- Overall Survival (OS); Time from CAR-T infusion to death from any cause
- Cmax; cellular kinetics of CAR-T - maximum expression observed in peripheral blood after a single administration (% copies/µg) over 24 months of observation
- Tmax; CAR-T cellular kinetics - time to maximum copy number in peripheral blood after a single administration (days) over 24 months of observation
- AUC0-30d and 90d; CAR-T cellular kinetics - AUC from day 0 to day 30 and 90 or other days as assessed in peripheral blood (% copies/µg x days)
- AUC0-Tmax; CAR-T cellular kinetics - AUC from day 0 to Tmax in peripheral blood (% copies/µg/days)
- Percentage of patients enrolled in the study for whom the CAR-T product was manufactured
- Duration of response (time from finding CR or CRi to patient progression or death from any cause)
- Percentage of CR or CRi patients with persistent B-cell aplasia after CAR-T cell infusion over 24 months of follow-up. Absolute CD19(+) lymphocyte count < 50/µl
研究者
Grzegorz Basak
Scientific
Medical University Of Warsaw
研究点 (3)
Loading locations...
相似试验
招募中
2 期
DK-CLIC-1901 CAR T-cells for treatment of patients with relapsed/refractory CD19 positive hematological malignancies (DAN-CART 1901)2024-515174-27-00Rigshospitalet20
招募中
2 期
CARLA-M19 : “Prospective non-randomized phase I/II study investigating the safety of CD19 CAR-T cells in patients with refractory/relapsed AML (Acute Myeloïd Leukemia) expressing CD19.”2023-509212-29-01Centre Hospitalier Universitaire De Lille5
招募中
2 期
A Phase 2 Study of the Efficacy and Safety of a Dose of Donor-Derived CD19-targeted CAR T cells.2024-516091-15-00Nosokomeio Paidon I Agia Sofia8
尚未招募
1 期
CD19/BCMA CAR-T for SLENCT07266337Chengdu Ucello Biotechnology Co., Ltd.24
招募中
1 期
A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS, PMS, or
MG(Breakfree-2)2023-507820-22-00Celgene Corp.56